Extended survival with metastatic pancreatic cancer under fruquintinib treatment after failed chemotherapy: Two case reports
Description
CONCLUSION: Both cases achieved a PFS benefit from later-line single-agent fruquintinib therapy. With its better safety profile, fruquintinib may be worth exploring and studying in more depth as a later-line treatment for pancreatic cancer patients.
